Literature DB >> 6653644

Pharmacokinetics of methadone in methadone maintenance treatment: characterization of therapeutic failures.

M I Nilsson, L Grönbladh, E Widerlöv, E Anggård.   

Abstract

Deuterated methadone (M-d3) and GC-MS analysis were used to study the steady state pharmacokinetics of methadone (M) in eight patients reported as therapeutic failures in a methadone maintenance treatment programme. The patients were compared to an unselected group of 12 patients stabilized on M for 25 days. During one dosage interval a pulse dose of M-d3 was administered intravenously instead of the oral M-dose (M-d0). The pharmacokinetic parameters, half-life in the beta-phase (t1/2 beta), volume of distribution during the postdistributive phase (Vd beta) and during steady state (Vdss) were determined as well as the body (ClS) and renal (ClR) clearances of M. Pronounced differences in Vd beta and Vdss were found between the two groups. The therapeutic failures had a smaller Vd beta and Vdss 3.09 +/- 0.96 1/kg and 2.74 +/- 0.96 1/kg vs 4.56 +/- 1.00 1/kg and 4.20 +/- 0.78 1/kg in the control group. The differences were due to changes between the groups in the volume of the central compartment. Differences between the groups were also found in t1/2 beta - 24.5 +/- 2.6 h in the therapeutic failures and 34.0 +/- 7.0 h (p less than 0.001) in the comparison group. However, the change in t1/2 beta was probably a consequence of the change in Vd beta, as the body clearance of M was similar in the two groups - 104 +/- 36 ml/min vs 111 +/- 36 ml/min. The smaller volume of distribution could lead to unacceptably high fluctuation of M in the central compartment, and withdrawal symptoms during the latter part of the dosage interval.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6653644     DOI: 10.1007/BF00542117

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  4 in total

1.  Plasma levels and symptom complaints in patients maintained on daily dosage of methadone hydrochloride.

Authors:  W H Horns; M Rado; A Goldstein
Journal:  Clin Pharmacol Ther       Date:  1975-06       Impact factor: 6.875

2.  The Swedish methadone maintenance program: a controlled study.

Authors:  L M Gunne; L Grönbladh
Journal:  Drug Alcohol Depend       Date:  1981-06       Impact factor: 4.492

3.  Methadone maintenance: plasma levels and therapeutic outcome.

Authors:  J Holmstrand; E Anggård; L M Gunne
Journal:  Clin Pharmacol Ther       Date:  1978-02       Impact factor: 6.875

4.  Pharmacokinetics of methadone during maintenance treatment: adaptive changes during the induction phase.

Authors:  M I Nilsson; E Anggård; J Holmstrand; L M Gunne
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

  4 in total
  11 in total

1.  Population pharmacokinetics of methadone in opiate users: characterization of time-dependent changes.

Authors:  A Rostami-Hodjegan; K Wolff; A W Hay; D Raistrick; R Calvert; G T Tucker
Journal:  Br J Clin Pharmacol       Date:  1999-07       Impact factor: 4.335

2.  Pharmacokinetics of methadone in HIV-positive patients receiving the non-nucleoside reverse transcriptase efavirenz.

Authors:  Rosario Calvo; John C Lukas; Monica Rodriguez; M Angeles Carlos; Elena Suarez
Journal:  Br J Clin Pharmacol       Date:  2002-02       Impact factor: 4.335

Review 3.  Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence.

Authors:  Chin B Eap; Thierry Buclin; Pierre Baumann
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

4.  Within- and between- subject variability in methadone pharmacokinetics and pharmacodynamics in methadone maintenance subjects.

Authors:  Julia Hanna; David J R Foster; Amy Salter; Andrew A Somogyi; Jason M White; Felix Bochner
Journal:  Br J Clin Pharmacol       Date:  2005-10       Impact factor: 4.335

5.  Steady-state pharmacokinetics of methadone in opioid addicts.

Authors:  K Wolff; A W Hay; D Raistrick; R Calvert
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

6.  Pharmacokinetics of methadone and its primary metabolite in 20 opiate addicts.

Authors:  J W de Vos; P J Geerlings; W van den Brink; J G Ufkes; H van Wilgenburg
Journal:  Eur J Clin Pharmacol       Date:  1995       Impact factor: 2.953

Review 7.  Pharmacological maintenance treatments of opiate addiction.

Authors:  James Bell
Journal:  Br J Clin Pharmacol       Date:  2014-02       Impact factor: 4.335

8.  Dose, Plasma Level, and Treatment Outcome Among Methadone Patients in Shanghai, China.

Authors:  Haifeng Jiang; Maureen Hillhouse; Jiang Du; Shujun Pan; Ang Alfonso; Jun Wang; Zhirong Zhou; Weijun Yuan; Walter Ling; Min Zhao
Journal:  Neurosci Bull       Date:  2016-09-10       Impact factor: 5.203

9.  Three Mutations Convert the Selectivity of a Protein Sensor from Nicotinic Agonists to S-Methadone for Use in Cells, Organelles, and Biofluids.

Authors:  Anand K Muthusamy; Charlene H Kim; Scott C Virgil; Hailey J Knox; Jonathan S Marvin; Aaron L Nichols; Bruce N Cohen; Dennis A Dougherty; Loren L Looger; Henry A Lester
Journal:  J Am Chem Soc       Date:  2022-04-21       Impact factor: 16.383

10.  Methadone as a "Tumor Theralgesic" against Cancer.

Authors:  Marta Michalska; Arndt Katzenwadel; Philipp Wolf
Journal:  Front Pharmacol       Date:  2017-10-31       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.